Tier 2 — strong

Fenofibrate causes elevation of betaine excretion but not excretion of other osmolytes by healthy adults

Michael Lever, Christopher J McEntyre, Peter M George, Sandy Slow, Stephen T Chambers, Christelle Foucher
Journal of clinical lipidology 2014 8(4):433-440

Bibliography

PubMed
PMID 25110225
DOI
10.1016/j.jacl.2014.04.001
Funding
Funding was not specified in the indexed record or accessible funding metadata.
Competing interests
A competing-interest declaration was not available in the indexed record or accessible disclosure metadata.

Study snapshot

DesignBefore-and-after drug study
ModelHuman participants
Sample26 healthy adults
InterventionMeasured betaine status and related metabolites; no randomized TMG treatment
Duration6 weeks of fenofibrate 145 mg/day
EndpointsUrinary betaine loss; Fenofibrate

What the study showed, in plain terms

Published in 2014, this source examined human observational and biomarker research. Design: Before-and-after drug study. Sample/model: 26 healthy adults. The exposure or intervention was Measured betaine status and related metabolites; no randomized TMG treatment. Follow-up or treatment period: 6 weeks of fenofibrate 145 mg/day.

Fenofibrate increased urinary betaine loss about threefold without a comparable rise in most other osmolytes.

Observational exposure analysis: residual confounding and reverse causation remain possible. Associations do not establish that betaine supplementation causes the same outcome.

Continue with TMG Data Center

Continue with TMG Supplement: Trimethylglycine Benefits, Uses and Evidence

Key findings

  • Fenofibrate increased urinary betaine loss about threefold without a comparable rise in most other osmolytes.
  • The recorded outcome domains were Urinary betaine loss; Fenofibrate.
  • The result applies to the tested exposure: Measured betaine status and related metabolites; no randomized TMG treatment; 6 weeks of fenofibrate 145 mg/day.

What this study can and cannot tell us

  • Observational exposure analysis: residual confounding and reverse causation remain possible. Associations do not establish that betaine supplementation causes the same outcome.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Indexed abstract and bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 4
Dietary Choline and Betaine and Risk of CVD: A Systematic Review and Meta-Analysis of Prospective Studies
Katie A Meyer et al. · Nutrients · 2017
Tier 4
Dietary Choline and Betaine Are Not Associated With the Risk of Type 2 Diabetes. A Systematic Review and Meta-Analysis of Observational Studies
Elham Sharifi-Zahabi et al. · Journal of diabetes research · 2026
Tier 4
Association of choline and betaine with the risk of cardiovascular disease and all-cause mortality: Meta-analysis
Qinglin Yang et al. · European journal of clinical investigation · 2023
Tier 4
Association of choline and betaine levels with cancer incidence and survival: A meta-analysis
Jiyoung Youn et al. · Clinical nutrition (Edinburgh, Scotland) · 2019

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology